UPDATE 3-U.S. House Democrats slam Valeant's drug price hikes; shares sink

Mon Sep 28, 2015 8:27pm EDT
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article | Single Page
[-] Text [+]

(Adds Chaffetz, 8th paragraph)

By Ransdell Pierson and Bill Berkrot

Sept 28 (Reuters) - Democratic lawmakers on Monday attacked "massive" price increases of two heart drugs by Canada's Valeant, fueling a rout in drugmaker shares on worries of a government and insurer clampdown on U.S. drug prices.

All 18 Democratic members of the House of Representatives Committee on Oversight and Government Reform urged their chairman to subpoena Valeant Pharmaceuticals International Inc and force it to provide documents relating to price increases of 212 percent for Isuprel and 525 percent for Nitropress. Valeant boosted the prices immediately after buying the heart drugs last February.

Shares of Valeant tumbled 16.5 percent on the New York Stock Exchange, and other pharmaceutical company shares also slid. Investors are worried that the drug industry faces a moment of reckoning for steep price hikes for both new and older medicines.

Shares of many pharmaceutical companies have slumped since 2016 Democratic presidential hopeful Hillary Clinton last week proposed ways for the government to prevent "profiteering" by the industry.

The slump in Valeant shares on Monday hit hedge funds run by activist investors Bill Ackman, John Paulson and Jeffrey Ubben.

Ackman's fund, Pershing Square Capital Management, owns nearly 5.76 percent of Valeant, which partnered with Ackman last year in a failed bid to acquire Botox-maker Allergan Plc .

The Nasdaq Biotech Index sank 6 percent, while the ARCA Pharmaceuticals Index of large drugmakers dropped 3.5 percent. AbbVie Inc, Eli Lilly & Co and Gilead Sciences Inc were among the hardest hit.   Continued...